Literature DB >> 15485764

Increaseed expression of mRNA for regulator of G protein signaling domain-containing Rho guanine nucleotide exchange factors in aorta from stroke-prone spontaneously hypertensive rats.

Zhekang Ying1, Liming Jin, Anne M Dorrance, R Clinton Webb.   

Abstract

BACKGROUND: Rho guanine nucleotide exchange factors (RhoGEF) link activation of G protein-coupled receptors (GPCR) to RhoA/Rho-kinase signaling. This cellular signaling pathway regulates vascular tone and is implicated in hypertension. The RhoGEF, providing this coupling, contain the regulator of G protein signaling (RGS) domain. We hypothesized higher mRNA expression levels for these RhoGEF in aorta from stroke-prone spontaneously hypertensive rats (SHRSP).
METHODS: We measured mRNA expression by semiquantitative reverse transcriptase-polymerase chain reaction in the aorta of Wistar-Kyoto rats (WKY) and SHRSP. The protein expression level of p115RhoGEF was examined by Western Blot, too.
RESULTS: Our results showed that mRNA for RGS domain containing RhoGEF is higher in SHRSP.
CONCLUSION: The results of this study indicate that RhoGEF may contribute to increased activation of RhoA/Rho-kinase pathway in hypertension.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15485764     DOI: 10.1016/j.amjhyper.2004.05.006

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  15 in total

Review 1.  The role of Rho protein signaling in hypertension.

Authors:  Gervaise Loirand; Pierre Pacaud
Journal:  Nat Rev Cardiol       Date:  2010-08-31       Impact factor: 32.419

2.  Erectile function in two-kidney, one-clip hypertensive rats is maintained by a potential increase in nitric oxide production.

Authors:  A Elizabeth Linder; Anne M Dorrance; Thomas M Mills; R Clinton Webb; Romulo Leite
Journal:  J Sex Med       Date:  2009-03       Impact factor: 3.802

3.  p63RhoGEF couples Gα(q/11)-mediated signaling to Ca2+ sensitization of vascular smooth muscle contractility.

Authors:  Ko Momotani; Mykhaylo V Artamonov; Darkhan Utepbergenov; Urszula Derewenda; Zygmunt S Derewenda; Avril V Somlyo
Journal:  Circ Res       Date:  2011-09-01       Impact factor: 17.367

Review 4.  Involvement of Rho GTPases and their regulators in the pathogenesis of hypertension.

Authors:  Gervaise Loirand; Pierre Pacaud
Journal:  Small GTPases       Date:  2014-10-31

Review 5.  Angiotensin II and Cardiovascular-Renal Remodelling in Hypertension: Insights from a Human Model Opposite to Hypertension.

Authors:  Verdiana Ravarotto; Elisa Pagnin; Antonio Fragasso; Giuseppe Maiolino; Lorenzo A Calò
Journal:  High Blood Press Cardiovasc Prev       Date:  2015-03-11

Review 6.  Mechanistic approach to the pathophysiology of target organ damage in hypertension from studies in a human model with characteristics opposite to hypertension: Bartter's and Gitelman's syndromes.

Authors:  L A Calò; G Maiolino
Journal:  J Endocrinol Invest       Date:  2015-03-05       Impact factor: 4.256

7.  p115 RhoGEF activates the Rac1 GTPase signaling cascade in MCP1 chemokine-induced vascular smooth muscle cell migration and proliferation.

Authors:  Nikhlesh K Singh; Jagadeesh Janjanam; Gadiparthi N Rao
Journal:  J Biol Chem       Date:  2017-06-27       Impact factor: 5.157

8.  Sphingosine 1-phosphate receptor 2 signals through leukemia-associated RhoGEF (LARG), to promote smooth muscle cell differentiation.

Authors:  Matt D Medlin; Dean P Staus; Adi D Dubash; Joan M Taylor; Christopher P Mack
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-08-11       Impact factor: 8.311

9.  PYK2/PDZ-RhoGEF links Ca2+ signaling to RhoA.

Authors:  Zhekang Ying; Fernanda R C Giachini; Rita C Tostes; R Clinton Webb
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-10       Impact factor: 8.311

Review 10.  Cellular mediators of renal vascular dysfunction in hypertension.

Authors:  Bharathy Ponnuchamy; Raouf A Khalil
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-02-18       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.